Lexicon Pharmaceuticals (NASDAQ:LXRX) Issues Quarterly Earnings Results, Beats Expectations By $0.80 EPS

Lexicon Pharmaceuticals (NASDAQ:LXRX) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.31 by $0.80, Fidelity Earnings reports. The business had revenue of $294.45 million for the quarter, compared to the consensus estimate of $12.00 million. Lexicon Pharmaceuticals’s quarterly revenue was up 4124.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) EPS.

NASDAQ:LXRX traded down $0.36 during trading hours on Friday, hitting $3.52. 1,316,800 shares of the company’s stock traded hands, compared to its average volume of 1,292,482. Lexicon Pharmaceuticals has a 52 week low of $1.13 and a 52 week high of $9.15. The firm has a market cap of $419.77 million, a P/E ratio of -3.09 and a beta of 0.95. The business’s fifty day simple moving average is $3.52 and its two-hundred day simple moving average is $4.21.

Several equities research analysts recently issued reports on LXRX shares. Citigroup lowered Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $3.00 to $4.00 in a research note on Friday. Stifel Nicolaus lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price objective for the company from $10.00 to $4.00 in a research note on Monday, July 29th. G.Research raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Gabelli raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research note on Wednesday, September 11th. Finally, BidaskClub lowered Lexicon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. Lexicon Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $6.45.

In other Lexicon Pharmaceuticals news, Director Christopher J. Sobecki purchased 25,000 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Monday, September 16th. The shares were bought at an average price of $2.55 per share, for a total transaction of $63,750.00. Following the acquisition, the director now directly owns 112,493 shares in the company, valued at $286,857.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Lonnel Coats purchased 37,000 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average price of $1.35 per share, for a total transaction of $49,950.00. Following the acquisition, the chief executive officer now owns 87,695 shares in the company, valued at $118,388.25. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 255,749 shares of company stock worth $578,510. 6.40% of the stock is owned by company insiders.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Read More: Differences Between Momentum Investing and Long Term Investing

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.